Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole Spheroid vs Tablet PD Study in GERD
NCT00195208Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pantoprazole in gastroesophageal reflux disease (GERD) and erosive esophagitis (EE) (2 arms), sponsored by Pfizer. Primary endpoint: Maximal Acid Output. Started Jun 2005; status: completed.
02
Drugs
pantoprazole
03
Conditions
gastroesophageal reflux disease (GERD)erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT00195208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195208.